Based on sales of its Posicam PET systems during the past nine months, Positron of Houston has announced record earnings. Growth in the modality has helped fuel Positron's recovery.The company reported third quarter (ended Sept. 30) revenue of $3.4
Based on sales of its Posicam PET systems during the past nine months, Positron of Houston has announced record earnings. Growth in the modality has helped fuel Positron's recovery.
The company reported third quarter (ended Sept. 30) revenue of $3.4 million, compared with $385,000 for the same period a year ago. In addition, Positron had a $1.1 million profit for the first nine months, compared with $108,000 for the same period in 1999.
Positron was plucked from the financial brink a year and a half ago by EBCT manufacturer Imatron (SCAN, 5/13/98). That company saw an opportunity in Japan, where hospitals were developing cardiac scanning facilities that would employ both PET and ultrafast CT. As Imatron gained majority ownership of Positron, Imatron CFO Gary Brooks took over as Positron's CEO.
Imatron has divested most of its Positron shares, and now owns 16% of its stock, Brooks said. Imatron CEO Lewis Meyer remains Positron's board chairman.
"We're gearing up and settling some obligations from years past," said Mike Golden, Positron's controller. "We're looking for incremental growth."
New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography
October 10th 2024Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.